These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Shares of GH Research PLC GHRS have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the ...

Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...

Depression is a pervasive mental health condition affecting millions of people worldwide. It can manifest in various ways, from persistent sadness to a lack of energy or interest in daily activities.

Dr. Muir is a dual board-certified psychiatrist in both child and general psychiatry, with expertise in managing complex mood disorders. He serves as a Clinical Assistant Professor of Medicine at the ...

One of the biggest challenges in cancer treatment is addressing the ability of cancer cells to adapt and become resistant, ...

Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

GH Research shares were up 801 to $19.15 after the company said the primary endpoint was met in a Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with ...

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...